Oncostatin M Is Related to Polycystic Ovary Syndrome-Case Control Study.

Oncostatin M, a novel adipokine, plays a role in oogenesis, lipogenesis, and inflammation and may contribute to polycystic ovary syndrome pathogenesis and related metabolic problems. Adipokines are believed to contribute to developing polycystic ovary syndrome and its accompanying metabolic parameters, such as dyslipidemia, insulin resistance, and cardiovascular diseases. In this case-control study, the patients were grouped in a 1:1 ratio into either the polycystic ovary syndrome ( 32) or the control group ( 32).